Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population

Drug Metabolism and Pharmacokinetics

Volumn 32, Issue 3, 2017, Pages 189-191

  Adehin, Ayorinde ^a   Bolaji, Oluseye Oladotun ^a   Kennedy, Martin A ^b  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

CYP2C8; CYP3A5; Drug metabolism; Genetic polymorphism; Nigerians

Indexed keywords

AMODIAQUINE; CHLOROQUINE; CYTOCHROME P450 2C8; CYTOCHROME P450 3A5; ERLOTINIB; EVEROLIMUS; GENOMIC DNA; IMATINIB; PACLITAXEL; TACROLIMUS; VALSARTAN; CYTOCHROME P450 3A;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME METABOLISM; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALARIA; MALE; NIGERIAN; PANCREAS ADENOCARCINOMA; PREVALENCE; SANGER SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPEUTIC INDEX; TUMOR XENOGRAFT; GENETIC POLYMORPHISM; GENETICS; METABOLISM; NIGERIA;

CYTOCHROME P-450 CYP2C8; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; MALE; NIGERIA; POLYMORPHISM, GENETIC;

EID: 85017556253     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.1016/j.dmpk.2016.09.001     Document Type: Article

References (29)

1. Totah, R.A., Rettie, A.E., Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77 (2005), 341–352.
2. Zhou, S.F., Liu, J.P., Chowbay, B., Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41 (2009), 89–295.
3. Motshoge, T., Tawe, L., Muthoga, C.W., Allotey, J., Romano, R., Quaye, I., et al. Cytochrome P450 2C8*2 allele in Botswana: human genetic diversity and public health implications. Acta Trop 157 (2016), 54–58.
4. Dai, D., Zeldin, D.C., Blaisdell, J.A., Chanas, B., Coulter, S.J., Ghanayem, B.I., et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11 (2001), 597–607.
5. Tsukada, C., Saito, T., Maekawa, M., Mano, N., Oda, A., Hirasawa, N., et al. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation. Drug Metab Pharmacokinet 30 (2015), 366–373.
6. Pechandova, K., Buzkova, H., Matouskova, O., Perlik, F., Slanar, O., Genetic polymorphisms of CYP2C8 in the Czech Republic. Genet Test Mol Biomarkers 16 (2012), 812–816.
7. Paganotti, G.M., Gramolelli, S., Tabacchi, F., Russo, G., Modiano, D., Coluzzi, M., et al. Distribution of human CYP2C8*2 allele in three different African populations. Malar J, 11, 2012, 125.
8. Chen, Z., Li, J., Chen, P., Wang, F., Zhang, N., Yang, M., et al. Genetic polymorphisms of the drug-metabolizing enzyme cytochrome P450 3A5 in a Uyghur Chinese population. Xenobiotica 7 (2016), 1–7.
9. Zanger, U.M., Schwab, M., Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138 (2013), 103–141.
10. Tishkoff, S.A., Reed, F.A., Friedlaender, F.R., Ehret, C., Ranciaro, A., Froment, A., et al. The genetic structure and history of Africans and African Americans. Science 324 (2009), 1035–1044.
11. Walle, T., Walle, U.K., Kumar, G.N., Bhalla, K.N., Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 23 (1995), 506–512.
12. Weise, A., Grundler, S., Zaumsegel, D., Klotzek, M., Gröndahl, B., Forst, T., et al. Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab 50 (2004), 141–148.
13. Nakajima, M., Fujiki, Y., Noda, K., Ohtsuka, H., Ohkuni, H., Kyo, S., et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 31 (2003), 687–690.
14. Marwa, K.J., Schmidt, T., Sjögren, M., Minzi, O.M., Kamugisha, E., Swedberg, G., Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J, 3, 2014 420.
15. The 1000 genome project. http://www.1000genomes.org. [Accessed 22.08.2016].
16. Paganotti, G.M., Gallo, B.C., Verra, F., Sirima, B.S., Nebié, I., Diarra, A., et al. Human genetic variation is associated with Plasmodium falciparum drug-resistance. J Infect Dis 204 (2011), 1772–1778.
17. Cabaleiro, T., Román, M., Ochoa, D., Talegón, M., Prieto-Pérez, R., Wojnicz, A., et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos 41 (2013), 224–229.
18. Oyekunle, A.A., Durosinmi, M.A., Bolarinwa, R.A., Owojuyigbe, T., Salawu, L., Akinola, N.O., Chronic myeloid leukemia in nigerian patients: anemia is an independent predictor of overall survival. Clin Med Insights Blood Disord 20 (2016), 9–13.
19. Filppula, A.M., Neuvonen, M., Laitila, J., Neuvonen, P.J., Backman, J.T., Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos 41 (2013), 50–59.
20. Backman, J.T., Filppula, A.M., Niemi, M., Neuvonen, P.J., Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev 68 (2016), 168–241.
21. Tanno, L.K., Kerr, D.S., dos Santos, B., Talib, L.L., Yamaguti, C., Rodrigues, H., et al. The Absence of CYP3A5*3 is a protective factor to anticonvulsants hypersensitivity reactions: a case-control study in brazilian subjects. PLoS One, 10, 2015 e0136141.
22. Fernandez, P., Zeigler-Johnson, C.M., Spangler, E., van der Merwe, A., Jalloh, M., Gueye, S.M., et al. Androgen metabolism gene polymorphisms, associations with prostate cancer risk and pathological characteristics: a comparative analysis between south african and senegalese men. Prostate Cancer, 2012, 2012, 798634.
23. Bains, R.K., Kovacevic, M., Plaster, C.A., Tarekegn, A., Bekele, E., Bradman, N.N., et al. Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. BMC Genet, 14, 2013, 34.
24. Hiratsuka, M., Takekuma, Y., Endo, N., Narahara, K., Hamdy, S.I., Kishikawa, Y., et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58 (2002), 417–421.
25. Luo, X., Zhu, L.J., Cai, N.F., Zheng, L.Y., Cheng, Z.N., Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5*3 genotype in Chinese renal transplant recipients. Acta Pharmacol Sin 37 (2016), 555–560.
26. Noll, E.M., Eisen, C., Stenzinger, A., Espinet, E., Muckenhuber, A., Klein, C., et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 22 (2016), 278–287.
27. Mukonzo, J.K., Waako, P., Ogwal-Okeng, J., Gustafsson, L.L., Aklillu, E., Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans. Ther Drug Monit 32 (2010), 346–352.
28. Lesche, D., Sigurdardottir, V., Setoud, R., Englberger, L., Fiedler, G.M., Largiadèr, C.R., et al. Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation. Clin Transpl 29 (2015), 1213–1220.
29. Tian, Y., Shen, S., Jiang, Y., Shen, Q., Zeng, S., Zheng, J., CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine. Arch Toxicol 90 (2016), 1737–1748.